行情

CLDX

CLDX

塞德斯医疗
NASDAQ

实时行情|Nasdaq Last Sale

17.53
-0.45
-2.50%
盘后: 17.53 0 0.00% 16:03 01/15 EST
开盘
17.88
昨收
17.98
最高
18.29
最低
17.37
成交量
43.83万
成交额
--
52周最高
23.40
52周最低
1.500
市值
6.94亿
市盈率(TTM)
-7.8911
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
2020年成长强劲的10只医疗保健股
Many of the best stocks in 2020 were healthcare companies focused on two disease areas: trying to stop the spread of COVID-19 and improving survival rates from deadly diseases. Their scientific achievements have been nothing less than extraordinary.
Benzinga · 2020/12/16 14:59
Celldex在慢性诱导性荨麻疹中对CDX-0159的1b期研究中的第一位患者
Celldex Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria HAMPTON, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the first patient
Benzinga · 2020/12/09 13:02
The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 24)
Benzinga · 2020/11/25 12:35
The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 23)
Benzinga · 2020/11/24 13:12
The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12)
Benzinga · 2020/11/13 12:40
The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 11)
Benzinga · 2020/11/12 12:44
2 Biotech Stocks That Keep on Climbing
finviz · 2020/10/16 00:14
Celldex Initiates Early-Stage Antibody Study for Skin Disorder
finviz · 2020/10/14 15:32
更多
财务预测
每股收益每股净资产每股现金流
实际值(美元)
预测值(美元)
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解CLDX最新的财务预测,通过CLDX每股收益,每股净资产,每股现金流等数据分析塞德斯医疗近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测CLDX价格均价为26.33,最高价位32.00,最低价为22.00。
EPS
机构持股
总机构数: 145
机构持股: 4,399.43万
持股比例: 111.19%
总股本: 3,956.71万
类型机构数股数
增持
26
404.62万
建仓
55
257.31万
减持
13
264.29万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.34%
制药与医学研究
+0.21%
高管信息
Chairman/Independent Director
Karen Shoos
Chief Executive Officer/President/Director
Anthony Marucci
Chief Financial Officer/Senior Vice President/Secretary
Sam Martin
Executive Vice President/Chief Scientific Officer
Tibor Keler
Senior Vice President/General Counsel
Freddy Jimenez
Senior Vice President/IR Contact Officer
Sarah Cavanaugh
Senior Vice President
Elizabeth Crowley
Senior Vice President
Margo Heath-Chiozzi
Senior Vice President
Ronald Pepin
Senior Vice President
Richard Wright
Senior Vice President
Diane Young
Independent Director
Keith Brownlie
Independent Director
Herbert Conrad
Independent Director
James Marino
Independent Director
Harry Penner
  • 分红
  • 拆股
  • 内部人交易
暂无数据
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取
CLDX 简况
Celldex Therapeutics, Inc.是一家生物制药公司。该公司致力于开发和商业化治疗癌症与其他疾病的多种免疫治疗技术。该公司的主导药物Rintega(也称为rindopepimut和CDX-110)是一种治疗胶质母细胞瘤的治疗性疫苗。该公司的Glembatumumab vedotin(也称为CDX-011)用于治疗转移性黑色素瘤。该公司的Varlilumab(也称为CDX-1127)是一种免疫调节抗体。该公司处于临床开发早期阶段的候选药物包括CDX-1401,一种治疗癌症适应症的靶向抗原呈递细胞(APC)的免疫治疗;以及作为免疫细胞动员剂和树突状细胞生长因子的CDX-301。该公司拥有一个多方面的肿瘤相关巨噬细胞(TAM)项目。该公司的产品还包括人源化单克隆抗体CDX-0158和CDX-3379。
展开
热门股票
代码
价格
涨跌幅

微牛提供Celldex Therapeutics, Inc.(NASDAQ-CLDX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CLDX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CLDX股票基本功能。